Recent advances of kinesin motor inhibitors and their clinical progress

Area of Science:

• Oncology
• Pharmacology
• Cell Biology

Background:

• Antimitotic chemotherapy, including vinca alkaloids and taxanes, is a cornerstone in treating various human neoplasms.
• Despite clinical success, acquired resistance and neurotoxicity limit the long-term efficacy of current tubulin-targeting agents.
• Tumor resistance and drug toxicity necessitate the development of more selective and less cytotoxic antimitotic therapies.

Purpose of the Study:

• To review the progress and potential of novel mitosis-specific agents in cancer therapy.
• To highlight kinesin motor inhibitors as a promising class of next-generation antimitotics.
• To discuss the advantages of targeting proteins predominantly functioning in mitosis.

Main Methods:

• Literature review of preclinical and clinical studies on antimitotic agents.
• Focus on the development and mechanism of action of kinesin motor inhibitors.
• Analysis of selectivity and cytotoxicity profiles of novel antimitotic compounds.

Main Results:

• Kinesin motor inhibitors represent a new frontier in antimitotic drug development.
• These agents exhibit potential for higher selectivity and reduced cytotoxicity compared to established drugs.
• Targeting mitotic kinesins offers a strategy to overcome existing drug resistance mechanisms.

Conclusions:

• Kinesin motor inhibitors show significant promise for improving cancer treatment outcomes.
• These novel agents may offer a more effective and safer alternative to current chemotherapy.
• Further research into kinesin motor inhibitors is crucial for advancing cancer therapy.